Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04998201 · ClinicalTrials.gov registry record · Phase 2
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
A Phase 2 study, sponsored by Arrowhead Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 353
- Enrollment target
NCT04998201 is a Phase 2 study that has completed, run by Arrowhead Pharmaceuticals. The registered enrollment target is 353 participants.
The verdict
NCT04998201, a Phase 2 study, has completed, sponsored by Arrowhead Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 353 participants
- Enrollment target
Study Summary
Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standards of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.
Interventions
- DRUG Placebo
- DRUG ARO-APOC3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2023-08-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04998201
The ClinicalTrials.gov registry entry for NCT04998201 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04998201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04998201 about?
NCT04998201 is a clinical study titled "Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia". Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recom...
What is the current status of trial NCT04998201?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 353 participants. The study started on 2021-09-28. Estimated completion is 2023-08-14.
What interventions are being tested in trial NCT04998201?
The interventions under investigation include: Placebo (DRUG), ARO-APOC3 (DRUG).
Who is sponsoring clinical trial NCT04998201?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.